Laurens E. Franssen

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Inger S. Nijhof, Laurens E. Franssen, Mark‐David Levin et al. · Blood · 2016 · 56 citations · Full text

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma

Laurens E. Franssen, Mieke W.H. Roeven, Willemijn Hobo et al. · Bone Marrow Transplantation · 2017 · 28 citations

Vaccination, Vaccine Development, Immunology +9

Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients

Rimke Oostvogels, Evelien Kneppers, Monique C. Minnema et al. · Bone Marrow Transplantation · 2016 · 27 citations

Vaccination, Immunology, Therapeutic Vaccine +10

The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs

Laurens E. Franssen, Niels W.C.J. van de Donk, Maarten E. Emmelot et al. · Bone Marrow Transplantation · 2015 · 22 citations

Hematological Malignancy, Autoimmune Disease, Malignant Blood Disorder +13

Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma

Marian F. Schmitz, Henny G. Otten, Laurens E. Franssen et al. · Haematologica · 2014 · 22 citations · Full text